{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:04:30Z","timestamp":1757455470770},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 34-year-old man with history of Hodgkin lymphoma presented 7 months after allogeneic stem cell transplantation with an unexplained severe musculoskeletal pain syndrome. A <jats:sup>99m<\/jats:sup>Tc-MDP bone SPECTCT showed multiple foci with moderate to intense bone uptake across the axial and appendicular skeleton consistent with periostitis. The patient had been on voriconazole daily for 4 months to treat an Aspergillus pneumonia, and in the absence of other causes, a drug-induced periostitis was suspected. Voriconazole was changed to posaconazole with complete resolution of the musculoskeletal symptoms within 3 weeks.<\/jats:p>","DOI":"10.1097\/rlu.0000000000002383","type":"journal-article","created":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T01:36:12Z","timestamp":1543973772000},"page":"159-160","source":"Crossref","is-referenced-by-count":6,"title":["Voriconazole-Induced Periostitis After Allogeneic Stem Cell Transplantation"],"prefix":"10.1097","volume":"44","author":[{"given":"Maarten","family":"Haemels","sequence":"first","affiliation":[{"name":"Nuclear Medicine and Molecular Imaging"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Pans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Schoemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolien","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Gheysens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sander","family":"Jentjens","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and Molecular Imaging"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20230928","first-page":"793","article-title":"Periostitis secondary to prolonged voriconazole therapy in a lung transplant recipient","volume":"34","year":"2011","journal-title":"Orthopedics"},{"key":"bib2-20230928","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00256-010-0997-y","article-title":"Medication-induced periostitis in lung transplant patients: periostitis deformans revisited","volume":"40","year":"2011","journal-title":"Skeletal Radiol"},{"key":"bib3-20230928","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1148\/rg.2017160052","article-title":"Hypertrophic osteoarthropathy: clinical and imaging features","volume":"37","year":"2017","journal-title":"Radiographics"},{"key":"bib4-20230928","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1146\/annurev.pharmtox.41.1.443","article-title":"Metabolism of fluorine-containing drugs","volume":"41","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"bib5-20230928","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/cid\/ciu513","article-title":"Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain","volume":"59","year":"2014","journal-title":"Clin Infect Dis"},{"key":"bib6-20230928","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/cid\/ciq188","article-title":"Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy","volume":"52","year":"2011","journal-title":"Clin Infect Dis"},{"key":"bib7-20230928","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1182\/blood-2012-01-403030","article-title":"Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole","volume":"120","year":"2012","journal-title":"Blood"},{"key":"bib8-20230928","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.1128\/AAC.00872-15","article-title":"Voriconazole enhances the osteogenic activity of human osteoblasts in vitro through a fluoride-independent mechanism","volume":"59","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"bib9-20230928","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1128\/AAC.05275-11","article-title":"Fluoride excess in coccidioidomycosis patients receiving long-term antifungal therapy: an assessment of currently available triazoles","volume":"56","year":"2012","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003072-201902000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T23:27:54Z","timestamp":1695857274000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201902000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002383","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}